Medication Antiparkinsonienne et Bilan Extra-Pyramidal: Etude du Trihexyphenidyl

Bordeleau, Jean-Marc; Albert, Jean-Marie; Hillel, J.; Tétreault, L

doi:10.1177/070674376701200608

Cited by 16 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some patients could present more than one type o f dyskinesia according to our scale. The parkinsonian symptoms were also assessed by means o f a rating scale (Bordeleau et al 1967). For the analysis o f the results, the first o f the two assessments prior to the study was discarded to avoid the emotional contamination that could have influenced the dyskinetic movements due to the exposure to a new situation.…”

Section: Experimental Designmentioning

confidence: 99%

Estrogens in Tardive Dyskinesia in Male Psychiatric Patients

Villeneuve¹,

T²,

Cote³

1980

Neuropsychobiology

View full text Add to dashboard Cite

The beneficial effect of estrogens on L-dopa-induced dyskinesias and on tardive dyskinesia has recently been reported. In this open pilot study, conjugated estrogens (CE) were administered to 20 male chronic psychiatric patients (age range: 29-63). All except 1 were still on neuroleptic medication and 8 of them were still receiving an antiparkinsonian agent. Patients were divided into 4 equal groups. Groups I and II (< 51 years old) received daily CE at different doses (1.25 or 2.50 mg) for a period of 6 weeks. Groups III and IV (> 52 years old) were treated identically. A significant decrease (p < 0.006) in intensity or disappearance of one type of dyskinesia was observed in each group (4 of 5 patients). No definite trend was noted in neuroleptic-induced parkinsonism, or apparent change in the mental condition of the patients. The functioning of the extrapyramidal system reveals itself therefore, increasingly complex if this antidopaminergic action of estrogens is added. Indeed, it had been hypothesized lately that in addition to dopamine and acetylcholine, substances like GABA and enkephalin could also be involved in its regulation. The relationship between dopamine and estrogens is interesting as the presence of catechol estrogens, compounds that might play an important role in neuroendocrine regulation, has been demonstrated in some areas of rat brain. Finally, with respect to hormones, the reported prompt and transitory rise in serum prolactin level after electroconvulsive therapy (ECT) may reflect a possible involvement of endorphins, at least in part, in the therapeutic effect of ECT. The possible influence of this form of treatment on extrapyramidal symptoms in relation with this is briefly discussed.

show abstract

Section: Experimental Designmentioning

confidence: 99%

Estrogens in Tardive Dyskinesia in Male Psychiatric Patients

Villeneuve¹,

T²,

Cote³

1980

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…At the end of each phase, psychopathology was evaluated by the Brief Psychiatric Rating Scale (BPRS) (7), and overt extrapyramidal side effects were evaluated using a scale modified after Bordeleau et al (3). Cogentin requirements were not considered in these extrapyramidal side effect ratings.…”

Section: Assessment Proceduresmentioning

confidence: 99%

Fluphenazine Decanoate and Fluphenazine Enanthate in the Out-Patient Management of Chronic Schizophrenia

et al. 1978

View full text Add to dashboard Cite

39 chronic schizophrenic out-patients were given either fluphenazine decanoate or enanthate for a 1-year double-blind trial. Doses of 25 mg were given for the first 6 months and 37.5 mg for the last 6 months. For both agents the intervals between treatments lengthened significantly over the course of the trial. Fluphenazine decanoate showed a non-significant trend for a longer duration of action coupled with a significantly lower incidence of extrapyramidal side effects.

show abstract

“…les deux semaines par la suite, I. apparItIOn des effets secondaires extrapyramidaux fut mesuree par notre echelle: Ie bilan extra-pyramidal (B.E.P.) (1). Un bilan biologique comprenant les analyses suivantes fut fait au meme moment: hemogramrne, prothrombine, analyse d'urine, azotemie, glycemie et tests de la fonction hepatique, (\'P" /' ", …”

unclassified

Utilisation Du Thiothixène Dans Le Traitement De La Manie: Étude Pilote

Filotto

Tétreault

1968

Canadian Psychiatric Association Journal

Self Cite

View full text Add to dashboard Cite

Nine manic patients have been the subjects of a pilot study with a new thioxanthene derivative, thiothixene. Data obtained from two rating scales indicate a significant improvement of the mental and behavioural conditions after three weeks of treatment. Thiothixene like other well-known neuroleptics induces extra-pyramidal symptoms and this tends to confirm the fact that thiothixene is a neuroleptic. The drug was well tolerated; however, we observed a decrease of prothrombin time in four patients.

show abstract

Medication Antiparkinsonienne et Bilan Extra-Pyramidal: Etude du Trihexyphenidyl

Abstract: •Une subvention fut offerte par Lederle Pharmaceu ticals pour la realisation de cette etude; directeur me dical; docteur Claude Gendron. Communication presentee a la session pleniaire As semble Annuelle de l'Association des

Cited by 16 publications

References 3 publications

Estrogens in Tardive Dyskinesia in Male Psychiatric Patients

Estrogens in Tardive Dyskinesia in Male Psychiatric Patients

Fluphenazine Decanoate and Fluphenazine Enanthate in the Out-Patient Management of Chronic Schizophrenia

Utilisation Du Thiothixène Dans Le Traitement De La Manie: Étude Pilote

Contact Info

Product

Resources

About